Comparative Pharmacology
Head-to-head clinical analysis: MESTINON versus PYRIDOSTIGMINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MESTINON versus PYRIDOSTIGMINE BROMIDE.
MESTINON vs PYRIDOSTIGMINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, preventing breakdown of acetylcholine and increasing its concentration at cholinergic synapses, thereby enhancing neuromuscular transmission.
Reversible acetylcholinesterase inhibitor, prolonging the action of acetylcholine at nicotinic and muscarinic receptors.
Myasthenia gravis: 60-150 mg orally every 3-4 hours, up to 1.2 g/day. Extended-release: 180-540 mg orally once or twice daily.
Oral: 60-120 mg every 3-4 hours (max 360 mg/day). Intravenous: 0.1-0.25 mg/kg IV (max 10 mg per dose) for reversal of nondepolarizing neuromuscular blockade, given with glycopyrrolate or atropine. Intramuscular: 0.2-1 mg for postoperative urinary retention.
None Documented
None Documented
The terminal elimination half-life is approximately 1.5 to 2 hours in adults. In patients with renal impairment, half-life may be prolonged (up to 6-10 hours in severe impairment), necessitating dose adjustment.
Terminal half-life: 1-2 hours (prolonged in renal impairment; up to 6 hours in anuria)
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of elimination, with a small fraction (10-20%) eliminated in feces via biliary secretion.
Renal: 70-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor